Strategic partnerships Target funded collaborations with biopharma companies developing targeted therapies for solid tumors, leveraging BioMarker’s SnapPath functional signaling profiles to assess pharmacodynamic responses and inform companion diagnostics.

Predictive biomarker edge Leverage SnapPath and PathMAP to offer live-tumor cell based pharmacodynamic insights, enabling partners to de-risk clinical programs and optimize patient selection for targeted treatments.

Clinical stage opportunities Position SnapPath as a translational tool for early clinical studies to assess pharmacodynamic changes, opening conversations with sponsors conducting first-in-class or combination therapy trials.

Portfolio expansion Explore licensing or service collaborations to broaden usage of SnapPath in preclinical tumorgraft studies and early pharmacodynamic assessments across additional solid tumor indications.

Competitive differentiation Highlight the live-cell based predictive capability versus traditional static biomarkers to differentiate offerings from larger CROs and sequencing-focused competitors, targeting mid- to late-stage oncology programs.